Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Treatment Patterns and Outcomes of Patients With HER2-Altered Metastatic Breast Cancer in the United States

NCT07342309 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07342309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07342309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Treatment Patterns and Outcomes of Patients With HER2-Altered Metastatic Breast Cancer in the United States
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Active, not recruiting
Start date
September 30, 2025
Completion date
October 30, 2026
Enrollment
7,933 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer